ECT204 transgene-transduced autologous T cells ECT204

A preparation of autologous human T lymphocytes transduced with a lentiviral vector expressing the ECT204 transgene that encodes an antibody-based antigen-binding domain targeting the tumor-associated antigen (TAA) glypican-3 (GPC3) and an effector-binding domain, with potential immunomodulating and antineoplastic activities. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the ECT204 transgene-transduced autologous T cells ECT204 target and bind to tumor cells expressing GPC3. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of GPC3-positive tumor cells. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed on normal, healthy cells. GPC3 plays an important role in cellular proliferation and differentiation.Compared to conventional CAR T cells, ECT204 may be less likely to stimulate cytokine release syndrome (CRS) and other cytokine-mediated toxicities.